Celyad , a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the infusion of the first patient of the second cohort of its Phase I clinical trial evaluating the Company's NKG2D CAR T-Cell therapy in acute myeloid leukaemia and multiple myeloma indications. Dr. Christian Homsy, CEO of Celyad, said : " The treatment of the first patient enrolled in the second cohort of our first-in-man Phase I trial evaluating NKG2D CAR T-Cells demonstrates continued progress in developing our lead immune-oncology program.